Bioptis SA
Bioptis reported total assets of €1.07m at the end of the 2025 financial year (annual accounts filed with the NBB on 12 Aug 2026).
The score of Bioptis shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity -3 % Total assets -5 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Bioptis's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 12 Aug 2026
- Year ended 31 Dec 2024filed on 28 Aug 2025
- Year ended 31 Dec 2023filed on 29 Jul 2024
- Year ended 31 Dec 2022filed on 27 Jul 2023
- Year ended 31 Dec 2021filed on 18 Jul 2022
Bioptis's financial analysis
- Solvency98.3%sector median: 56.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Bioptis
Bioptis's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0892.450.478
- VAT number
- BE0892450478
- Peppol
- Registered · 0208:0892450478 · as of 10 Nov 2026
- Legal form
- SA
- Incorporated
- 02 Oct 2007
- Registered office
- 6698 Vielsalm
- Latest accounts
- 2025 · filed on 12 Aug 2026
- Activity
- Manufacture of instruments and appliances for measuring, testing and navigation (NACE 26510)
Bioptis (SA) has been based in Vielsalm since 2007, active in: manufacture of instruments and appliances for measuring, testing and navigation. For 2025, it reports a net loss of 10,034 € and equity of €1.06m; its revenue is not published. Its solvency stands at 98.3%, above the median of its sector (56.2%).
Companies similar to Bioptis
Companies in the same business, of comparable size and area, outside its group.
- Sensor-Nite NV Manufacture of instruments and appliances for measuring, testing and navigation Antwerp · balance sheet €5.43m
- STL International Manufacture of instruments and appliances for measuring, testing and navigation Halen · balance sheet 712,489 €
- Consort Manufacture of instruments and appliances for measuring, testing and navigation Turnhout · balance sheet 886,787 €
- Micromeritics Manufacture of instruments and appliances for measuring, testing and navigation Brussels · balance sheet 983,998 €
- Conttech Manufacture of instruments and appliances for measuring, testing and navigation Asse · balance sheet 849,410 €
- Normalab Belgium Manufacture of instruments and appliances for measuring, testing and navigation Namur · balance sheet €1.23m
- iSystems Manufacture of instruments and appliances for measuring, testing and navigation Antwerp · balance sheet 905,158 €
- Movex Manufacture of instruments and appliances for measuring, testing and navigation Aartselaar · balance sheet 684,688 €
Frequently asked questions about Bioptis
What is the revenue of Bioptis?
Bioptis files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Bioptis?
In Belgium, the VAT number is the company number prefixed with BE: BE0892450478 for Bioptis, if the company is VAT-registered. Its company number (CBE) is 0892.450.478.
Where is the registered office of Bioptis?
According to the CBE register, the registered office of Bioptis is in 6698 Vielsalm.
What is the equity of Bioptis?
At the close of the 2025 financial year, the equity of Bioptis amounts to 1,055,052 €, a solvency of 98.3% of total assets.
Who manages Bioptis?
The register lists 14 active mandates at Bioptis. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Bioptis
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →